Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics, Inc. (NTLA) scores 33 out of 100 on boothcheck's 11-model valuation framework. Verdict: Strong Avoid The estimated fair value is $-42.02, representing a 68% margin of safety.

Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.

View full NTLA analysis on boothcheck